The company saw adjusted earnings-per-share grow 6.1% to $0.52 per share from $0.49 per share in the same quarter a year ago. Abbott Laboratories left its adjusted earnings-per-share guidance for full fiscal 2015 unchanged at $2.10 to $2.20 per share.
Abbott Laboratories has been the leading competitor in the drug-eluting stent (DES) market with over 30% market share. Their actual selling price for DES has been quite low due to competition with Boston Scientific.
Abbott Laboratories logo Shares of Abbott Laboratories (NYSE:ABT) have been given a consensus rating of “Buy” by the seventeen brokerages that are presently covering the stock, Analyst Ratings Network.
Our proven model does not conclusively shows that Abbott Labs is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an ...